Genomic Precision

 A SeraCare blog focused on precision medicine and advanced clinical diagnostics

AACR 2019 Day Three: Understanding T-cell Therapy for Unique Cancer Mutations

Posted by Catherine Huang on Apr 4, 2019 3:03:00 PM

My third day at the AACR Annual meeting was a day of phenomenal presentations. I am struggling to choose just one to tell you about because I attended multiple inspiring, thought-provoking, and even entertaining talks today. I decided to report on the plenary presentation by Steven A. Rosenberg entitled “T-cell therapy targeting unique cancer mutations” because I think this story has the most potential to positively impact patient outcomes.

Read More

Topics: cancer, AACR

AACR 2019 Day Two: Learning About the Microbiome in Immuno-Oncology

Posted by Catherine Huang on Apr 3, 2019 1:50:00 PM

At the AACR Annual Meeting, I was most excited to attend the major symposium entitled “The Microbiome as an Orchestrator of Immunity and Cancer Immunotherapy,” which featured three highly informative talks. First, Gregory Sonnenberg from Weill Cornell Medicine gave an overview of how the microbiome contributes to immune homeostasis in the intestine.

Read More

Topics: cancer, AACR

New Podcast: Target the Tumor Mutational Burden and Pursue Harmonization

A Featured Speaker Podcast by Friends of Cancer Research

Posted by Melinda Fayette on Mar 20, 2019 10:00:00 AM

Friends of Cancer Research aims to better understand the impact of assay variation on clinical outcomes, align standards, and define best practices for tumor mutational burden assessment. Harmonization of methods to quantify TMB will facilitate robust biomarker development and optimize clinical utilization and treatment decision-making. 

Read More

Topics: cancer, TMB

NTRK Fusion Testing for New Therapies

Detecting & Managing Rare Pediatric & Adult Cancers

Posted by Omo Clement, Ph.D. on Feb 6, 2019 9:15:00 AM

Neurotrophic tyrosine receptor kinases (NTRK) can become abnormally fused to other genes resulting in growth signals that can lead to cancer in many organs of the human body. TRK gene fusion-based cancers are rare but present in pediatric and adult cancers such as lung, thyroid, colon, etc. (see, e.g., Figure 1).

Read More

Topics: cancer, NTRK, RNA fusion

Developing a Rock-Solid Lung Cancer Assay, Part 2

Posted by Yves Konigshofer on Jul 2, 2018 4:45:00 PM

In a recent post, we discussed key considerations for designing a robust next-generation sequencing (NGS)-based lung cancer assay. Putting those plans into action in the development phase brings forth a new set of challenges. Through our experience developing NGS reference materials and the relationships we’ve built with assay developers of all stripes, we’ve identified those important factors and ways to navigate them. But before you begin designing and optimizing your assay, you should become very familiar with binomial and Poisson distributions and their use because the outcome of many analytical steps can be modeled and explained with them.

Read More

Topics: cancer, NGS, Assay Development, Lung Cancer

How A New Generation of ctDNA Reference Standards Are Enabling the Promise of Precision Medicine

Posted by Omo Clement, Ph.D. on Jun 14, 2018 10:00:00 AM

An important goal in cancer disease management is early detection. When detected early, disease progression can be significantly mitigated with a plethora of options (targeted therapy, chemotherapy, surgery, etc.) available to medical practitioners, to afford progression free survival and a higher quality of life. A great promise of liquid biopsies is the possibility of early detection of cancer long before clear evidence of lesions and tumor growth observable by imaging or other techniques.1 As proxy for solid tissue biopsies, plasma-based liquid biopsy application is rapidly gaining traction in cancer disease diagnosis, progression, monitoring, and in predicting resistance to treatment options.2

Read More

Topics: cancer, NGS, ctDNA, SeraSeq, liquid biopsy

Developing a Rock-Solid Lung Cancer Assay

Posted by Yves Konigshofer on Mar 15, 2018 11:55:00 AM

Next-generation sequencing (NGS) allows deeper insights than ever before into the human genome and a host of diseases and conditions. So it makes sense that there is a worldwide movement to employ NGS in a growing number of applications. But as the saying goes, with great power comes great responsibility.



Read More

Topics: cancer, NGS, reference materials, Lung Cancer

CNVs and Tumor Profiling: New CNV Materials for Breast, Lung, and Brain Cancer

Posted by Dana Ruminski Lowe, Ph.D. on Feb 14, 2018 4:00:00 PM

Simply described, copy number variations (CNVs) are DNA segments present at a variable copy number in comparison to a normal genome. It was originally thought that a CNV consisted of a region of greater than 1 kilobases, however advances in technology have allowed for identification of CNVs as small as 50 basepairs1.

Read More

Topics: cancer, NGS, reference materials

With so many options, how do you select the best NGS cancer assay?

Posted by Catherine Huang on Jan 11, 2018 12:10:00 PM

Clinical labs must constantly evolve their test offerings in order to support the most recent advances in clinical care. For next-generation sequencing (NGS) tumor profiling assays, there are often multiple commercially available kits with similar claims for gene content and sensitivity, as well as customized solutions. How can you quickly perform an effective evaluation of available assay systems to make a data-driven choice?

Read More

Topics: cancer, NGS, reference materials, RNA fusion

How Many Target Copies Are Present in Your Plasma DNA Sample?

A 0.1% measurement requires a reasonable amount of input material

Posted by Dale Yuzuki on Jun 15, 2017 1:30:00 PM

The field of circulating tumor DNA analysis (ctDNA, also sometimes called in a larger context “liquid biopsy”) holds great promise for monitoring response to cancer treatment, assisting therapeutic choice, monitoring recurrence, and for pre-cancer screening. As such there is a great amount of assay development and ongoing clinical trials; at ClinicalTrials.gov searching for the term "Circulating DNA" you can find over 180 open clinical trials for a wide range of tumor types and interventions.

Read More

Topics: cancer, ctDNA, liquid biopsy, Assay Development